HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecamonica screening programme, Northern Italy.


Journal

Journal of medical screening
ISSN: 1475-5793
Titre abrégé: J Med Screen
Pays: England
ID NLM: 9433359

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 28 2 2020
medline: 16 6 2021
entrez: 28 2 2020
Statut: ppublish

Résumé

To present performance indicators from the second round of the Vallecamonica-Sebino HPV screening programme in women who had tested negative about four years earlier (mean 45 months). From 2010 to 2012, the target female population (aged 25-64) was invited to the first HPV screening round. In 2013-2017, women were rescreened for the second round. HPV-negative women at the first round were initially rescreened after three years. The interval was gradually increased to five years. HPV-positive women underwent cytology triage: positives were referred to colposcopy and negatives to repeat testing after one year. If HPV was persistently positive, women were referred to colposcopy, if negative, to normal interval rescreening. In the second round, of 13,824 previously HPV-negative women, 598 were HPV-positive (4.3%), of whom 297 were positive at cytology triage. Of those referred to one-year HPV test, 291 complied (98.0%), 133 (50.2%) of whom were persistently positive. Total referral was 3.1% compared with 6.6% in the first round (age-adjusted relative referral 0.59, 95% CI: 0.53-0.65). There were 24 cervical intraepithelial neoplasia 2+ (three cervical intraepithelial neoplasia 3+). Detection was 0.17%, compared with 0.9% in the first round. Age-adjusted relative detections were 0.25 (95% CI: 0.16-0.39) and 0.18 (95% CI: 0.05-0.61) for cervical intraepithelial neoplasia 2+ and cervical intraepithelial neoplasia 3+, respectively. Positive predictive value was 5.7%, compared with 14.6% in the first round. At second round, referral was half that at first round, while cervical intraepithelial neoplasia 2+ detection decreased nine-fold. Consequently, positive predictive value decreased dramatically. Rescreening four years after an HPV-negative test makes the process inefficient due to the low prevalence of lesions.

Identifiants

pubmed: 32102618
doi: 10.1177/0969141320905325
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

207-214

Auteurs

Luigi Pasquale (L)

Former responsible for screening ex ASL Vallecamonica-Sebino, Regione Lombardia, Breno, Italy.

Paolo G Rossi (PG)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Francesca Carozzi (F)

S.C. Laboratorio di Prevenzione Oncologica, Istituto per lo Studio e la Prevenzione Oncologica, Firenze, Italy.

Serena Domenighini (S)

ATS Montagna, Regione Lombardia, Sondrio, Italy.

Cristina Ruggeri (C)

ATS Montagna, Regione Lombardia, Sondrio, Italy.

Lorella Cecconami (L)

ATS Montagna, Regione Lombardia, Sondrio, Italy.

Corrado Morana (C)

ASST Valcamonica, Regione Lombardia, Esine, Italy.

Margherita Chiaramonte (M)

ATS Montagna, Regione Lombardia, Sondrio, Italy.

Daniela Chiudinelli (D)

ASST Valcamonica, Regione Lombardia, Esine, Italy.

Manuela Piccolomini (M)

ASST Valcamonica, Regione Lombardia, Esine, Italy.

Roberta Marchione (R)

ASST Valcamonica, Regione Lombardia, Esine, Italy.

Massimo Confortini (M)

S.C. Laboratorio di Prevenzione Oncologica, Istituto per lo Studio e la Prevenzione Oncologica, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH